<< Back to all news coverage

Cardiac Interventions Today: March 2018

VEST Evaluates Wearable Defibrillator for Patients After a Heart Attack

Findings from the Vest Prevention of Early Sudden Death Trial (VEST) are reviewed with commentary from Dr. Jeffrey Olgin, co-principal investigator, in this article by Cardiac Interventions Today. VEST is the first multi-center, randomized controlled trial of the wearable cardioverter defibrillator (WCD).The VEST Trial studied 2,302 patients who had a recent MI and a low-EF.

Dr. Olgin is Professor and Chief of Cardiology, University of California San Francisco in San Francisco, California.

Recommended use of the WCD is included in the AHA/ACC/HRS Guidelines for a wide range of patients at risk of sudden cardiac death (SCD), including those who have recently suffered a myocardial infarction (MI), with or without revascularization, and those with a newly diagnosed non-ischemic dilated cardiomyopathy.

<< Back to all news coverage